Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel

Danhier, Fabienne; Vroman, Benoît; Lecouturier, Nathalie; Crokart, Nathalie; Pourcelle, Vincent; Freichels, Hélène; Jérôme, Christine; Marchand‐Brynaert, Jacqueline; Feron, Olivier; Préat, Véronique

doi:10.1016/j.jconrel.2009.08.011

Cited by 316 publications

(204 citation statements)

References 47 publications

Supporting

Mentioning

196

Contrasting

Unclassified

Order By: Relevance

“…They observed that RGD-grafted nanoparticles were more associated with human umbilical vein endothelial cells in vitro by binding to α v β 3 integrin than were nontargeted nanoparticles, and they also demonstrated the targeting of RGD and RGD peptidomimetic-grafted nanoparticles to tumor vessels, as well as effective retardation of transplantable liver tumor growth and prolonged survival times in mice treated by paclitaxel-loaded RGD nanoparticles when compared with nontargeted nanoparticles. 134 The folate receptor is a highly specific tumor marker that is overexpressed in many human cancers. In addition, this receptor is absent in most normal tissues, so is frequently exploited for drug-targeting purposes.…”

Section: Ligand-receptor Interactionmentioning

confidence: 99%

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Dinarvand¹,

Sepehri²,

Manoochehri³

et al. 2011

IJN

390

265

View full text Add to dashboard Cite

The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been developed using different polymers with or without surface modification to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a biodegradable polyester approved for human use, has been used extensively. Here we report on recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review the methods used for the preparation and characterization of PLGA nanoparticles and their applications in the delivery of a number of active agents. Increasing experience in the field of preparation, characterization, and in vivo application of PLGA nanoparticles has provided the necessary momentum for promising future use of these agents in cancer treatment, with higher efficacy and fewer side effects.

show abstract

Section: Ligand-receptor Interactionmentioning

confidence: 99%

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Dinarvand¹,

Sepehri²,

Manoochehri³

et al. 2011

IJN

390

265

View full text Add to dashboard Cite

show abstract

“…Moreover, it has low tensile strength (~23 MPa), but very high elongation at breakage (4700 %) making it a good elastic biomaterial [81] [182]. PCL is used in the production of implants composed of adhered nano/microspheres [183], electrospun fibers [184,185], or porous networks [186] used for regeneration of bone [187,188], ligament [189,190], cartilage [191], nerve [192], and vascular tissues [193]. In addition, PCL is often blended or copolymerized with other polymers like polyesters and polyethers to expedite overall polymer erosion [194].…”

Section: Polyestersmentioning

confidence: 99%

Biodegradable polymers for dental tissue engineering and regeneration

Conte¹,

Riccitiello²,

Luise³

et al. 2017

Biodegradable Polymers: Recent Developments and New Perspectives

View full text Add to dashboard Cite

“…α v β 3 integrin is overexpressed in both tumour cells and angiogenic endothelial cells, making it a potential target for therapy [25]. Since the discovery that cyclic pentapeptides containing the amino acid sequence ArgGly-Asp (RGD) bind selectively to α v β 3 integrins [26] and they can enhance drug delivery to tumours [27], nanoparticles decorated with RGD-type peptides have been used in drug targeting [28][29][30][31][32][33][34]. Glioblastomas are aggressive, highly vascularized brain tumours that display poor patient survival and prognosis with current therapies.…”

Section: Introductionmentioning

confidence: 99%

Tumour targeting of lipid nanocapsules grafted with cRGD peptides

Hirsjärvi

Belloche

Hindré

et al. 2014

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Combining targeting to therapy remains a major challenge in cancer treatment. To address this subject, the surface of lipid nanocapsules (LNC) were modified by grafting cRGD peptides, which are known to be recognised by α v β 3 integrins expressed by tumour endothelium and cancer cells. Applicability of this LNC-cRGD in tumour targeting was first assessed in vitro by the use of U87MG glioma cells. Biodistribution and tumour accumulation of radiolabelled LNC-cRGD in vivo were then evaluated in mice bearing the same subcutaneous xenograft. Flow cytometry and confocal microscopy results revealed that the cRGD grafting improved binding and internalization compared to negative control LNCcRAD and blank LNC. The peptide-grafted LNC remained in the blood circulation up to 3 hours with reduced capture by the RES organs. Tumour accumulation of LNC-cRGD with respect to LNC-cRAD was significantly higher at 1-3 hours. These results show that cRGD grafted to LNC has created a promising tumour-targetable nanocarrier that could be used in cancer treatment.

show abstract

Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel

Cited by 316 publications

References 47 publications

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Biodegradable polymers for dental tissue engineering and regeneration

Tumour targeting of lipid nanocapsules grafted with cRGD peptides

Contact Info

Product

Resources

About